Table 4.
Concordance rates across groups based on actionable phenotypes and use of SSRIs
| Controls (N = 24) | Implementation (N = 25) | |||
|---|---|---|---|---|
| CYP2D6, N (%) | CYPC19, N (%) | CYP2D6, N (%) | CYP2C19, N (%) | |
| Total N (% of total) with potentially actionable phenotypes | 5 a (20.8) | 5 a (20.8) | 3 (12.0) | 9 (36.0) |
| Total N (% of actionable) with concordant medication changes if prescribed a medication | 2 (50.0) d | 4 (80.0) | 3 (100.0) | 8 (100.0) d |
| Total N with discordant actionable phenotypes in relation to medications taken at baseline. Note: total N on medications at baseline = 38 | 1 | 3 | 0 | 4 |
| Medication change, N | ||||
| Medication metabolized by the other CYP enzyme; no change required | 2 | 1 | 3 | 4 |
| Medication changed to one metabolized by the other CYP enzyme | 0 | 1 b | 0 | 1 c |
| Dose of medication changed | 0 | 2 | 0 | 3 |
SSRIs, selective serotonin reuptake inhibitors.
a
One patient had both an actionable phenotype for CYP2D6 and for CYP2C19.
b
Rapid metabolizer originally on escitalopram, switched to fluoxetine.
c
Ultra‐rapid metabolizer originally on sertraline, switched to duloxetine.
d
One individual never prescribed an SSRI throughout the study and was not counted as being concordant nor discordant.